present
data
phase
study
nash
aasld
liver
san
francisco
globe
newswire
nasdaq
etnb
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
treatment
liver
diseases
today
announced
clinical
data
phase
study
evaluating
glycopegylated
analog
patients
nonalcoholic
steatohepatitis
nash
presented
poster
liver
meeting
digital
american
association
study
liver
diseases
aasld
held
november
also
presenting
poster
preclinical
data
demonstrating
receptor
activation
profile
similar
native
poster
details
promising
clinical
profile
nash
measured
metabolic
parameters
favorable
safety
tolerability
profile
potential
dosing
presentation
details
follows
abstract
number
poster
title
demonstrated
robust
reductions
liver
favorable
tolerability
potential
every
weeks
dosing
phase
double
blind
multiple
ascending
dose
study
nash
presenting
author
rohit
loomba
director
nafld
research
center
professor
medicine
university
california
san
diego
abstract
number
poster
title
novel
glycopegylated
fibroblast
growth
factor
activates
fgf
receptors
fgfr
cells
transfected
four
different
human
fgfrs
beta
klotho
klb
presenting
author
moti
rosenstock
preclinical
development
nash
nash
advanced
stage
nonalcoholic
fatty
liver
disease
nafld
complex
metabolic
disorder
causes
fat
buildup
liver
well
inflammation
eventually
fibrosis
worsen
cirrhosis
liver
failure
nash
affects
million
adults
united
states
prevalence
predicted
increase
percent
exact
cause
nash
unknown
commonly
found
people
obesity
type
diabetes
currently
approved
treatments
biopharmaceutical
industry
actively
involved
addressing
unmet
medical
need
phase
study
clinical
study
multicenter
randomized
multiple
ascending
trial
designed
assess
safety
tolerability
pk
properties
well
change
liver
fat
measured
key
biomarker
assessments
subjects
nash
fibrosis
subjects
phenotypical
nash
pnash
pnash
defined
patients
steatosis
greater
central
obesity
type
diabetes
central
obesity
evidence
liver
injury
populations
enrolled
similar
disease
characteristics
baseline
total
subjects
randomized
receive
weekly
every
two
weeks
subcutaneous
dosing
placebo
weeks
results
observed
across
dose
groups
trial
add
growing
body
evidence
demonstrating
promise
treatment
nash
results
showed
robust
reductions
liver
fat
key
liver
markers
strong
efficacy
favorable
tolerability
observed
weekly
every
dosing
glycopegylated
analog
developed
treatment
nash
optimally
engineered
using
proprietary
glycopegylation
technology
balance
efficacy
longer
dosing
interval
recent
phase
data
show
demonstrated
favorable
safety
tolerability
profile
robust
reductions
liver
fat
key
lipid
markers
dosed
weekly
qw
every
two
weeks
also
developed
treatment
severe
hypertriglyceridemia
shtg
currently
phase
trial
biopharmaceutical
company
focused
development
commercialization
innovative
therapies
treatment
liver
diseases
company
lead
product
candidate
specifically
engineered
glycopegylated
analog
developed
treatment
nonalcoholic
steatohepatitis
nash
severe
hypertriglyceridemia
shtg
headquartered
san
francisco
operations
herzliya
israel
investor
contact
ryan
martins
chief
financial
officer
investors
media
contact
peter
duckler
pduckler
